Please login to the form below

Not currently logged in

Takeda's diabetes drug enters phase III

Takeda Pharmaceutical's TAK-875, a novel investigational therapy for diabetes, has entered phase III development

Takeda Pharmaceutical's TAK-875, a novel investigational therapy for diabetes, has entered phase III development.

TAK-875 is being investigated for its ability as an agonist of GPR40, a receptor in pancreatic islet cells, with Takeda hoping it can selectively improve glucose-dependent insulin secretion with a potential for reduced risk of hypoglycaemia.

It is the first such drug to reach the phase III stage of development.

Dr Thomas Strack, vice president, clinical science, Takeda Global Research & Development Center, US, said: "Takeda is committed to enhancing the clinical investigation of TAK-875 in order to accelerate the development of a potential new type 2 diabetes treatment option for patients and healthcare professionals."

The first phase III trial in the US/Europe programme will enrol about 450 patients with type 2 diabetes who are not adequately controlled on diet and exercise. The study's primary endpoint will be the change in blood glucose levels at week 24.

19th October 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...